AstraZeneca PLC (AZN.L)
Develops prescription medicines to treat cancer, heart disease, respiratory conditions, and rare diseases
12,940.00+0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+16.5%
The outlook
AstraZeneca is trading near the upper end of its 52-week range, with analyst sentiment leaning bullish and an average price target suggesting roughly 23% upside from current levels. The stock sits below both its 50- and 200-day moving averages, indicating a near-term pullback despite the broader positive analyst view. The trailing P/E of 25.9 reflects a premium valuation typical of the pharmaceutical sector.
What’s behind the score
Analyst consensusBuy — 1.9 avg of 22 analysts
Price trendBelow its 50- & 200-day averages
52-week range82% of the way from its 52-week low to high
Price targetAvg target +23% vs current price
Analyst price target
~12-month · 22 analysts15,893.76average target+22.8% vs now
Now 12,940.00
Low 11,425.81High 18,590.98
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$200.68B
52-wk high
15,732.00
52-wk low
0.00
50-day avg
13,492.48
200-day avg
13,861.50
Trailing P/E
25.9